WO2024030103A3 - Formulations comprising hyaluronic acid and cetyl myristoleate and the use of these formulations in the treatment of osteoarthritis - Google Patents

Formulations comprising hyaluronic acid and cetyl myristoleate and the use of these formulations in the treatment of osteoarthritis Download PDF

Info

Publication number
WO2024030103A3
WO2024030103A3 PCT/TR2023/050755 TR2023050755W WO2024030103A3 WO 2024030103 A3 WO2024030103 A3 WO 2024030103A3 TR 2023050755 W TR2023050755 W TR 2023050755W WO 2024030103 A3 WO2024030103 A3 WO 2024030103A3
Authority
WO
WIPO (PCT)
Prior art keywords
formulations
osteoarthritis
treatment
hyaluronic acid
cetyl myristoleate
Prior art date
Application number
PCT/TR2023/050755
Other languages
French (fr)
Other versions
WO2024030103A2 (en
Inventor
Neslihan ÜSTÜNDAĞ OKUR
Hatice Yeşim KARASULU
İlknur KESKIN
Mustafa ŞAHIN
Bahtiyar DEMIRALP
Yüksel ANTEPÜZÜMÜ BOLAT
Vildan YOZGATLI
Original Assignee
Istanbul Medipol Universitesi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Istanbul Medipol Universitesi filed Critical Istanbul Medipol Universitesi
Publication of WO2024030103A2 publication Critical patent/WO2024030103A2/en
Publication of WO2024030103A3 publication Critical patent/WO2024030103A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/52—Hydrogels or hydrocolloids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/22—Lipids, fatty acids, e.g. prostaglandins, oils, fats, waxes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/23—Carbohydrates
    • A61L2300/236—Glycosaminoglycans, e.g. heparin, hyaluronic acid, chondroitin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/45—Mixtures of two or more drugs, e.g. synergistic mixtures
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2400/00—Materials characterised by their function or physical properties
    • A61L2400/06—Flowable or injectable implant compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00—Materials or treatment for tissue regeneration
    • A61L2430/06—Materials or treatment for tissue regeneration for cartilage reconstruction, e.g. meniscus

Abstract

The invention relates to low-cost microemulsion and in-situ gel formulations with a long duration of efficacy for use in the treatment of osteoarthritis, which do not require repeated injections, and relates to the preparation method of these formulations and their use in the treatment of osteoarthritis.
PCT/TR2023/050755 2022-07-31 2023-07-31 Formulations comprising hyaluronic acid and cetyl myristoleate and the use of these formulations in the treatment of osteoarthritis WO2024030103A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
TR2022/012108 2022-07-31
TR2022012108 2022-07-31
TR2022015122 2022-10-03
TR2022/015122 2022-10-03

Publications (2)

Publication Number Publication Date
WO2024030103A2 WO2024030103A2 (en) 2024-02-08
WO2024030103A3 true WO2024030103A3 (en) 2024-03-14

Family

ID=89849964

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2023/050755 WO2024030103A2 (en) 2022-07-31 2023-07-31 Formulations comprising hyaluronic acid and cetyl myristoleate and the use of these formulations in the treatment of osteoarthritis

Country Status (1)

Country Link
WO (1) WO2024030103A2 (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030124200A1 (en) * 1999-06-22 2003-07-03 Stone Kevin R. Cartilage enhancing food supplements with sucralose and methods of preparing the same
US6677321B1 (en) * 1999-12-09 2004-01-13 Bruce Levin Methods and compositions for treatment of inflammatory disease
WO2008100628A2 (en) * 2007-02-16 2008-08-21 Synvista Therapeutics, Inc. Glutathione peroxidase mimetics for treatment of neurodegenerative, pulmonary and inflammatory diseases
CN105999273A (en) * 2016-05-24 2016-10-12 江南大学 Compound preparation for treating arthritis

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030124200A1 (en) * 1999-06-22 2003-07-03 Stone Kevin R. Cartilage enhancing food supplements with sucralose and methods of preparing the same
US6677321B1 (en) * 1999-12-09 2004-01-13 Bruce Levin Methods and compositions for treatment of inflammatory disease
WO2008100628A2 (en) * 2007-02-16 2008-08-21 Synvista Therapeutics, Inc. Glutathione peroxidase mimetics for treatment of neurodegenerative, pulmonary and inflammatory diseases
CN105999273A (en) * 2016-05-24 2016-10-12 江南大学 Compound preparation for treating arthritis

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CAO YIFENG, MA YIFENG, TAO YI, LIN WEIFENG, WANG PING: "Intra-Articular Drug Delivery for Osteoarthritis Treatment", PHARMACEUTICS, vol. 13, no. 12, CH , pages 1 - 20, XP093150017, ISSN: 1999-4923, DOI: 10.3390/pharmaceutics13122166 *

Also Published As

Publication number Publication date
WO2024030103A2 (en) 2024-02-08

Similar Documents

Publication Publication Date Title
WO2023283642A8 (en) Pan-human coronavirus concatemeric vaccines
WO2001091773A3 (en) Method of stimulating hair growth
Zidar et al. Treatment challenges and delivery systems in immunomodulation and probiotic therapies for periodontitis
WO2024030103A3 (en) Formulations comprising hyaluronic acid and cetyl myristoleate and the use of these formulations in the treatment of osteoarthritis
MX2017016227A (en) Broad-spectrum anti-infective peptides.
KR101767414B1 (en) cosmetic method of manufacture method
US6451773B1 (en) Chitosan formulation with azelaic acid and other actives for the treatment of acne
WO2000045847A8 (en) Novel mucosal delivery system
CN105899221B (en) Composition for skin based on algae and olive leaf extract
WO2016149376A1 (en) Treatment of acne vulgaris with sequential topical formulations comprising antimicrobial organic acid anions in alkaline phase
CN106491518B (en) Human-like collagen gynecological mucosa repair gel
US20040013622A1 (en) Cosmetic compositions for improving the health of nails
Rapala-Kozik et al. Interactions of Candida albicans cells with aerobic and anaerobic bacteria during formation of mixed biofilms in the oral cavity
CN102552882A (en) Application of LECT2 protein and LECT2 protein variant in pharmacy
WO2000033852B1 (en) Compound and method for degrading amino acids
HUE024108T2 (en) An agricultural composition, method for the production thereof and uses in the treatment of cultures
WO2019164872A3 (en) Composition and method for targeting natural killer cells in immunotherapy to overcome tumor suppression with manganese dioxide nanoparticles
US20060159646A1 (en) Hair regenerator
WO2020104943A3 (en) Safe and effective method of treating psoriasis with anti-il-23 specific antibody
WO2019156583A1 (en) Method for producing an agent for treatment of wounds
WO2023114557A3 (en) METHODS OF TREATING SUBSTANCE USE DISORDERS USING 5-MeO-DMT
WO2023104114A8 (en) Rna formulations and lipids
CN102366421A (en) Disinfectant
WO2021026455A3 (en) Antibiotic peptides, compositions and uses thereof
JP2017534689A5 (en)